Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 8Cardiotoxicity 5Heart Failure 3Sarcoma 1Lymphoma 1Hematologic Neoplasms 1Cardiomyopathies 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Carvedilol 3sacubitril and valsartan sodium hydrate drug combination 2dapagliflozin 2pertuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1Trastuzumab 1Specimen Handling 1Secondary Prevention 1Perindopril 1Ogivri 1Metoprolol 1Exercise 1Electronic Health Records 1Echocardiography 1Carnitine 1Bisoprolol 1Adrenergic beta-Antagonists 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Heart Failure × Carvedilol × Breast × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT04023110 2025-10-09

CCTGuide Pilot

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
68 enrolled 20 charts
Breast

Breast Neoplasms, Heart Failure, Cardiomyopathies, Cardiotoxicity

NCT01724450 2018-02-05

Ceccy

University of Sao Paulo

Phase 3 Completed
200 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡